Will Celgene Corporation (NASDAQ:CELG) burn you? Here’s some data to help answer that question. To many traders, hedge funds are perceived as overrated, outdated investment tools of a forgotten age.

Shares of Celgene, a biotech blue-chip stock that generates most of its revenue from the development of oncology, inflammation, and immunology drugs, dipped 11% in November, based on data from S&P ...

Following another successful quarterly report, investors and shareholders of Celgene have to be wondering if anything can stop this stock from heading higher. For the quarter, Celgene reported a sales ...

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative ...

SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced the election of John Weiland to its Board of Directors. Mr. Weiland has over 30 years in the healthcare industry and ...

Drugs can be like the stars. Some shine brightly. Some appear seemingly out of nowhere. And some grow dimmer over time and eventually disappear from the night sky. Celgene Corporation (NASDAQ:CELG) ...

As part of a new research deal with Celgene Corp., a startup with intriguing technology that could someday enable personalized medicine by letting doctors test different cancer drugs in a patient’s ...

The pharmaceutical industry underwent a major consolidation last year, driven by the loss of former top-selling drugs to the patent cliff, huge cash positions built up over the preceding decade, and ...

LOUISVILLE, Colo. & SUMMIT, N.J. - May 15, 2009 - GlobeImmune, Inc. and Celgene Corporation (NASDAQ: CELG) today announced a worldwide strategic collaboration focused on the discovery, development and ...

Company Reports Record Operating Performance in 2007 Driven by Extraordinary Revenue and Profit Growth - Total Revenue for 2007 Increased More Than 50 Percent Year-Over-Year to Approximately $1.4 ...

Celgene posted a solid third quarter earnings report with product sales up 19% -- with most of that coming from increases in volume -- and adjusted earnings per share up 24%. But when you dive down to ...